Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders
Autore:
Krystal, JH; DSouza, DC; Petrakis, IL; Belger, A; Berman, RM; Charney, DS; Abi-Saab, W; Madonick, S;
Indirizzi:
Connecticut Mental Hlth Ctr, Abraham Ribicoff Res Facil, New Haven, CT 06519 USA Connecticut Mental Hlth Ctr New Haven CT USA 06519 ew Haven, CT 06519 USA Yale Univ, Sch Med, Dept Psychiat, Div Cognit & Clin Neurosci, New Haven, CT USA Yale Univ New Haven CT USA Div Cognit & Clin Neurosci, New Haven, CT USA VA Connecticut Healthcare Syst, Psychiat Serv, W Haven, CT USA VA Connecticut Healthcare Syst W Haven CT USA hiat Serv, W Haven, CT USA
Titolo Testata:
HARVARD REVIEW OF PSYCHIATRY
fascicolo: 3, volume: 7, anno: 1999,
pagine: 125 - 143
SICI:
1067-3229(199909/10)7:3<125:NAAAAP>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
METHYL-D-ASPARTATE; VENTRAL TEGMENTAL AREA; EXCITATORY AMINO-ACIDS; POSTTRAUMATIC-STRESS-DISORDER; WITHDRAWAL-INDUCED ACTIVATION; LOCUS-COERULEUS NEURONS; D-CYCLOSERINE TREATMENT; LONG-TERM POTENTIATION; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Citazioni:
212
Recensione:
Indirizzi per estratti:
Indirizzo: Krystal, JH Connecticut Mental Hlth Ctr, Abraham Ribicoff Res Facil, 34 PkSt, New Haven, CT 06519 USA Connecticut Mental Hlth Ctr 34 Pk St New HavenCT USA 06519 SA
Citazione:
J.H. Krystal et al., "NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders", HARV R PSYC, 7(3), 1999, pp. 125-143

Abstract

Antagonists of the N-methyl-D-aspartate (NMDA) subclass of glutamate receptors and agonists of the glycine-B coagonist site of these receptors have been important tools for characterizing the contributions of NMDA receptor pathophysiology to a large number of neuropsychiatric conditions and for treating these conditions. Among these disorders are Alzheimer's disease, chronic pain syndromes, epilepsy, schizophrenia, Parkinson's disease, Huntington's disease, addiction disorders, major depression, and anxiety disorders. This review will examine pathophysiological and therapeutic hypotheses generated or supported by clinical studies employing NMDA antagonists and glycine-B agonists and partial agonists. It will also consider ethical issues related to human psychopharmacological studies employing glutamatergic probes.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/01/20 alle ore 12:27:13